HOME >> MEDICINE >> NEWS
Two years after gene therapy treatments, severe angina patients showed prolonged clinical benefit

Corautus Genetics Inc. (NASDAQ:VEGF) announced today the publication of the two year follow-up results of the Corautus' earlier Phase I study of VEGF-2 in patients with severe angina. In this trial, Vascular Endothelial Growth Factor-2 (VEGF-2), in the form of "naked" plasmid DNA (a non-viral delivery vector) was delivered in defined doses by direct injection into the heart muscle. Results of the follow-up study, as reported by the investigators in the current issue of the Journal of Interventional Cardiology (JOIC) (Vol. 18, No. 1, pp. 27 31, 2005), demonstrate prolonged clinical benefit as measured by improvement of patients' angina two years following treatment (p < 0.05) with no reported complications directly related to the gene therapy procedure. The Journal article and full publication are available on line at www.blackwellpublishing.com/joic .

Corautus' technology is currently being tested in a randomized, double-blinded, dose-ranging and placebo-controlled Phase IIb clinical trial known as GENASIS ("Genetic Angiogenic Stimulation Investigational Study"), which will enroll 404 patients with Class III or IV angina that are not suitable candidates for traditional revascularization procedures. The GENASIS trial will be conducted in approximately 25 cardiac medical centers throughout the United States. In the GENASIS trial, defined doses of VEGF-2 in the form of "naked" plasmid DNA are delivered to diseased heart muscle tissue via the Boston Scientific Corporation (NYSE: BSX) Stiletto(TM) endocardial direct injection catheter system. The injection procedure is performed by a cardiologist in a standard cardiac laboratory. Corautus expects to complete patient enrollment of the Phase IIb trial around the end of 2005.

Dr. Douglas W. Losordo, the national Principal Investigator for the GENASIS trial and Chief of Cardiovascular Research at Caritas St. Elizabeth's Medical Center in Bosto
'"/>

Contact: Justin Jackson
jjackson@burnsmc.com
212-213-0006
Burns McClellan
8-Mar-2005


Page: 1 2 3 4 5

Related medicine news :

1. Many children are undervaccinated or have delayed vaccinations in their first 2 years of life
2. 14-year study finds that quitting smoking adds years to life
3. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
4. Cumulative trauma in adulthood can worsen health in later years
5. Malnutrition in early years leads to low IQ and later antisocial behavior, USC study finds
6. Vioxx should have been withdrawn 4 years ago
7. Cancer burden seen even many years after diagnosis
8. Scientists meet to review Envisat results after two and a half years of operations
9. Study finds lung transplants increase survival of cystic fibrosis patients by more than four years
10. Full recovery after cell transplantation for treating leukemia or lymphoma can take 3-5 years
11. Full recovery after cell transplantation for treating leukemia or lymphoma can take 3-5 years

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2020)... , ... May 26, 2020 , ... ... coronavirus pandemic, medical centers across the United States are joining forces to start ... workers who have worked tirelessly to save lives. #FitForTheFrontLine is a national fitness ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... Guide to Coordinating Clinical Research, CenterWatch eLearning , https://www.centerwatch.com/products/category/2764-elearning/product/472-the-crc-trainer , ... Trainer: An Interactive Companion to the CRC’s Guide to Coordinating Clinical Research ...
(Date:5/21/2020)... , ... May 21, 2020 , ... ... manufacturer, announces its first milestone to deliver over one million FDA-compliant face shields ... Summit Medical Face Shields meet the critical need for personal protective equipment (PPE) ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... experience of GSCG, VITA NOVAS has already gained ground with the inherited reputation ... and stimulating biological products intravenously, guaranteeing an effective way for the ingredients to ...
(Date:5/21/2020)... ... 21, 2020 , ... Friends of Lisa Campbell, announce that Lisa Campbell, candidate ... Parenthood Southeast Advocates (PPSEA). PPSEA educates and lobbies on behalf of women’s ... of reproductive health care. PPSEA educates and lobbies on behalf of women’s health and ...
Breaking Medicine News(10 mins):
(Date:5/30/2020)... NEW YORK (PRWEB) , ... May 30, 2020 ... ... the world are dealing with a host of new issues related to COVID-19. ... discuss some tips to help expectant moms support their pregnancy and postpartum. ...
(Date:5/28/2020)... Ill. (PRWEB) , ... May 28, 2020 , ... ... telehealth and remote patient-care products led M&S Technologies, leader and innovator in essential ... introduction of M&S Technologies ’ web-based Vision Testing has been released and ...
(Date:5/27/2020)... ... May 27, 2020 , ... ... Jeffrey Taub , a biomedical engineer with more than 25 years of experience ... joined the firm as an Expert Consultant. His expertise includes quality assurance, including ...
Breaking Medicine Technology:
Cached News: